Neoantigen T Cell Therapy
Ovarian Cancer (and other solid malignancies)
Pre-clinicalActive
Key Facts
Indication
Ovarian Cancer (and other solid malignancies)
Phase
Pre-clinical
Status
Active
Company
About Singula Bio
Singula Bio is a UK-based, private biotech founded in 2019, originating from the University of Oxford. The company is developing a personalized cell therapy platform that identifies, expands, and reinfuses a patient's own tumor-specific T cells to target neoantigens in solid tumors. As a pre-clinical, pre-revenue entity, it aims to address the significant unmet need in solid tumor oncology by creating individualized therapies to prevent recurrence and improve survival.
View full company profile